open access

Vol 51, No 3 (2020)
REVIEW ARTICLE
Published online: 2020-09-01
Submitted: 2020-06-04
Get Citation

Chimeric antigen receptor T in the treatment of multiple myeloma – state of the art and future directions

Dominik Dytfeld
DOI: 10.2478/ahp-2020-0023
·
Acta Haematol Pol 2020;51(3):120-124.

open access

Vol 51, No 3 (2020)
REVIEW ARTICLE
Published online: 2020-09-01
Submitted: 2020-06-04

Abstract

In spite of the introduction of several new drugs in the last 10 years, multiple myeloma (MM) remains incurable. Thus, an adoptive cellular therapy using chimeric antigen receptor T (CART), a strategy to increase the frequency of tumor-directed and functionally active T cells targeting antigens present on the cancer cell, might change the treatment in MM as it did in lymphoma and ALL. There are several targets for CART therapy in MM on different levels of development, which are discussed in the manuscript. B-cell maturation antigen (BCMA) being tested in the studies of phase 1–2 is the most promising, but so far CART has not been approved in the cure of MM and remains an experimental approach. The hematological society is facing a new technology which with its potential ability to cure MM, in spite of its complexity, cost, and toxicity, will definitely and soon change the landscape of myeloma in Europe and world-wide.

Abstract

In spite of the introduction of several new drugs in the last 10 years, multiple myeloma (MM) remains incurable. Thus, an adoptive cellular therapy using chimeric antigen receptor T (CART), a strategy to increase the frequency of tumor-directed and functionally active T cells targeting antigens present on the cancer cell, might change the treatment in MM as it did in lymphoma and ALL. There are several targets for CART therapy in MM on different levels of development, which are discussed in the manuscript. B-cell maturation antigen (BCMA) being tested in the studies of phase 1–2 is the most promising, but so far CART has not been approved in the cure of MM and remains an experimental approach. The hematological society is facing a new technology which with its potential ability to cure MM, in spite of its complexity, cost, and toxicity, will definitely and soon change the landscape of myeloma in Europe and world-wide.

Get Citation

Keywords

myeloma; CART; immunotherapy

About this article
Title

Chimeric antigen receptor T in the treatment of multiple myeloma – state of the art and future directions

Journal

Acta Haematologica Polonica

Issue

Vol 51, No 3 (2020)

Pages

120-124

Published online

2020-09-01

DOI

10.2478/ahp-2020-0023

Bibliographic record

Acta Haematol Pol 2020;51(3):120-124.

Keywords

myeloma
CART
immunotherapy

Authors

Dominik Dytfeld

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

By "Via Medica sp. z o.o." sp.k., ul. Świętokrzyska 73, 80–180 Gdańsk, Poland
tel.:+48 58 320 94 94, fax:+48 58 320 94 60, e-mail: journals@viamedica.pl